Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results

Abstract

Objectives: To evaluate the short term efficacy and tolerability results of intravitreal aflibercept injection as a treatment option for eyes with chronic central serous chorioretinopathy (CSCR).

Material and methods: A prospective longitudinal study. Ten eyes of 10 patients with chronic CSCR who had been followed for >6months after the first intravitreal injection of aflibercept were recruited for the study. The best corrected visual acuity (BCVA) and central macular thickness (CMT) values obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the injection.

Results: The mean logMAR BCVA was 0.70±0.25 at baseline. At the first, third, and sixth months after the injection, the mean logMAR BCVA were 0.39±0.36, 0.32±0.39, and 0.29±0.34, respectively. The mean and median BCVA over the entire follow-up period was significantly improved compared with baseline BCVA (P<.05 for each one). The mean CMT was 449.30±142.53μm at baseline. It was measured as 302.60±72.28μm on the first month, 294.30±72.85μm on the third month, and 294.60±83.84μm on the sixth month after the injection. The mean and median CMT during the entire follow-up period was significantly decreased compared with baseline CMT (P<.05 for each one). None of the patients had any serious ocular or systemic side effects over the course of the study.

Conclusions: Short term results of this study demonstrate that intravitreal aflibercept may be used as a treatment option to improve the BCVA and reduce the CMT in chronic CSCR.

Keywords: Aflibercept; Agudeza visual; Central macular thickness; Central serous chorioretinopathy; Coriorretinopatía serosa central; Espesor macular central; Factor de crecimiento endotelial vascular; Vascular endothelial growth factor; Visual acuity.